Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Drug Metabolism and Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2133/DMPK.17.357PMID 15618686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population screening for isoniazid acetylator phenotype

  2001cited by this paper
• Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

  2000cited by this paper
• High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5' nuclease chain reaction assay.

  2000cited by this paper
• Isoniazid-induced fever.

  1996cited by this paper
• High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids.

  1995cited by this paper
• Nomenclature for N-acetyltransferases.

  1995cited by this paper
• Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

  1995cited by this paper
• Molecular analysis of the arylamine N‐acetyltransferase polymorphism in a Spanish population

  1994cited by this paper
• Molecular genotyping of N-acetylation polymorphism to predict phenotype

  1992cited by this paper
• Genetically determined differences in drug metabolism as a risk factor in drug toxicity.

  1992cited by this paper
• Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver.

  1990cited by this paper
• Human Arylamine N-Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional Expression

  1990cited by this paper
• Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver.

  1990cited by this paper
• N-acetyltransferase.

  1989cited by this paper
• Severe febrile reaction to isoniazid.

  1987cited by this paper
• Spiking Fever Induced by Isoniazid

  1983cited by this paper
• Isoniazid-induced fever.

  1979cited by this paper
• Genetical and Geographic Studies on Isoniazid Inactivation

  1961cited by this paper
• Chemotherapy of Experimental Tuberculosis. VIII. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds1,2

  1953cited by this paper
• THE CHEMOTHERAPY OF EXPERIMENTAL TUBERCULOSIS I

  1950cited by this paper
• Chemotherapy of Experimental Tuberculosis.

  1941cited by this paper

• Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review

  2025cites this paper
• CYP2E1 POLYMORPHISMS AND SUSCEPTIBILITY TO ANTI-TUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY IN INDONESIA POPULATION

  2025cites this paper
• Balance Between Phenotyping and Genotyping Methods of N-Acetyltransferase 2 in Tunisia and Comparison with Other Countries: A Rapid Review

  2024cites this paper
• Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

  2022cites this paper
• Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs

  2022cites this paper
• A case report of isoniazid adverse drug reaction in a pediatric patient with defective NAT2 gene

  2021cites this paper
• acetyltransferase 2 Polymorphism is Associated With Bladder Cancer Risk: An Updated Meta-Analysis Based on 54 Case-Control Studies.

  2020cites this paper
• A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.

  2020cites this paper
• Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China

  2020cites this paper
• Risk factors of isoniazid mono-resistance among pulmonary tuberculosis patients at Central Chest Institute of Thailand

  2020cites this paper
• Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

  2019cites this paper
• Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.

  2018cites this paper
• Acetylator Status on Tuberculosis Patients Receiving Isoniazid-Contained Antituberculosis Regiment

  2017cites this paper
• N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis

  2017cites this paper
• N-Acetyl Transferase (NAT) 2 Polymorphisms and Susceptibility to Antituberculosis Drug-induced Hepatotoxicity in Indonesia

  2017cites this paper
• A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy

  2016cites this paper
• Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients

  2016cites this paper
• NAT2 Genotype Pattern among Tuberculosis Patients Receiving Fixed-Dose Combination of Antituberculosis

  2016cites this paper
• Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients

  2016cites this paper
• Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?

  2016cites this paper
• Pharmacogenomics in drug development : implementation and application of PKPD model based approaches

  2015cites this paper
• Pharmacokinetic/pharmacodynamic relationship and simulation analysis for the evaluation of isoniazid hepatotoxicity risk development in patients with tuberculosis

  2015cites this paper
• Stepwise injection determination of isoniazid in human urine samples coupled with generalized calibration method

  2015cites this paper
• UNIVERSITÁ DEGLI STUDI DI UDINE

  2015cites this paper
• A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?

  2014cites this paper
• Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.

  2014cites this paper
• Chapter 36 – Tuberculosis

  2014cites this paper
• Age-distribution and genotype correlation for N Argentine children under isoniazid treatment

  2014cites this paper
• NAT2 gene polymorphisms in three indigenous groups in the Colombian Caribbean Coast region

  2014cites this paper
• Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy.

  2013cites this paper
• Full-Gene-Sequencing Analysis of N-Acetyltransferase-2 in an Adult Indian Population

  2013influential citation
• Pharmakogenetik in der Praxis: warum, wie, wann? Teil 2

  2012cites this paper
• Etude du polymorphisme génétique de la N-Acétyltransférase de type 2 dans la population sénégalaise : prévention de la toxicité et de l’échec thérapeutique de l’isoniazide dans la prise en charge de la tuberculose

  2012cites this paper
• Role of pharmacogenomics in the treatment of tuberculosis: a review

  2012cites this paper
• [Treatment of intractable tuberculous meningitis using intrathecal isoniazid administration and steroid pulse therapy; a report of two cases].

  2012cites this paper
• Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response.

  2012cites this paper
• Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.

  2012cites this paper
• Study of NAT2 Gene Polymorphisms in an Indian Population

  2012cites this paper
• ファーマコゲノミクス（PGx）情報を利用した個別化薬物療法の展開

  2012cites this paper
• Distal sensory polyneuropathy in HIV/TB co-infection: the role of vitamin B6 and N-acetyltransferase 2 genetic variation

  2012cites this paper
• Pharmacogenomics in Personalized Drug Therapy

  2012cites this paper
• Pharmacogenetics of Arylamine N-acetyltransferase genes in South African populations

  2012cites this paper
• Pharmacogenetics: The Scientific Basis

  2012cites this paper
• Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.

  2011cites this paper
• Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects

  2011cites this paper
• Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.

  2011cites this paper
• NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.

  2010cites this paper
• Genetic and ethnic risk factors associated with drug hypersensitivity

  2010cites this paper
• Estimating N-acetyltransferase metabolic activity and pharmacokinetic parameters of isoniazid from genotypes in Chinese subjects.

  2009cites this paper
• Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

  2009cites this paper
• Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky?

  2009cites this paper
• Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis.

  2008cites this paper
• Pharmacogenetic tools for malaria and TB in the Developing World.

  2008cites this paper
• Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature

  2008cites this paper
• Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.

  2008cites this paper
• Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.

  2008cites this paper
• N-Acetyltransferase Polymorphism Among Northern Sudanese

  2007cites this paper
• NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

  2007influential citation
• NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients.

  2007cites this paper
• The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid

  2007cites this paper
• Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.

  2007cites this paper
• PharmGED: Pharmacogenetic Effect Database

  2006cites this paper
• Implicaciones de los polimorfismos de un solo nucleótido en Mycobacterium tuberculosis y humanos en el manejo clínico de la tuberculosis

  2006cites this paper
• Aspectos metodológicos y éticos de la farmacogenómica en los ensayos clínicos aleatorizados

  2006cites this paper
• Can pharmacogenetics help rescue drugs withdrawn from the market?

  2006cites this paper
• The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.

  2006cites this paper
• Genetic testing for pharmacogenetics and its clinical application in drug therapy.

  2006cites this paper
• SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype

  2006cites this paper
• The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population

  2006influential citation
• Competitive allele-specific short oligonucleotide hybridization (CASSOH) with enzyme-linked immunosorbent assay (ELISA) for the detection of pharmacogenetic single nucleotide polymorphisms (SNPs).

  2006cites this paper
• Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

  2005influential citation
• Pharmacogenetics in drug regulation: promise, potential and pitfalls

  2005cites this paper
• Genotyping of single nucleotide polymorphisms (SNPs) influencing drug response by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.

  2004cites this paper
• The Journal of Toxicological Sciences

  2003cites this paper
• NAT 2 gene polymorphisms in three indigenous groups in the Colombian Caribbean Coast region Polimorfismo del Gen NAT 2 en tres grupos indígenas de la región Caribe Colombiana

  year unknowncites this paper